Skip to main content
. 2021 Jan 10;11(2):433–447. doi: 10.1007/s13555-020-00477-6

Table 1.

Clinician and patient characteristics

Clinician background and experience n = 7
Years treating and/or managing patients with AA, median (range) 20.0 (8.0–39.0)
Number of patients treated or managed in a typical montha, median (range)
 AA overall 90.0 (30.0–350.0)
 Severe AA (50–94% hair loss) 45.0 (20.0–200.0)
 Very severe AA (≥ 95% hair loss) 15.0 (3.0–50.0)
Patient demographic and clinical characteristics n = 15
Age (years), mean (range) 36.3 (18.0–60.0)
Male, n (%) 9 (60)
Education, highest level completed, n (%)
 High school, currently enrolled 1 (7)
 High school, graduated 2 (13)
 Junior/technical college, graduated 2 (13)
 University graduate school, graduated 10 (67)
Years since diagnosis, mean (range) 6.2 (1.1–22.1)
Months of current episode, mean (range) 3.7 (0.8–10.0)
Clinician-reported percentage of scalp hair loss, mean (range) 82.5 (50.0–100.0)
 Patients with ≥ 95% scalp hair loss, n (%) 9 (60)
 Years with ≥ 95% scalp hair loss, mean (range) 4.5 (0.8–7.0)
Treatment received for AA, n (%)b
 Corticosteroids (intralesional/topical/oral)c 12 (80)
 Topical immunotherapyd 4 (27)
 Local injection 2 (13)
 Oral antihistamine 1 (7)
 None 3 (20)
Concomitant illnesses, n (%)
 Allergic rhinitis 7 (47)
 Atopic dermatitis 7 (47)
 Asthma 6 (40)
 Anxiety 3 (20)
 Depression 2 (13)
 Hypertension 1 (7)
 Psoriasis 1 (7)

AA alopecia areata

aThe median value of ranges provided by one clinician (e.g., 40–50) was used to calculate the sample median

bCategories were not mutually exclusive

cFive patients received eyebrow corticosteroid injections only and three patients received two corticosteroids (topical and intralesional, topical and eyebrow injection, oral and topical)

dTopical immunotherapy includes diphencyprone, squaric acid dibutylester, and unspecified